MX2021010283A - Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus. - Google Patents

Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.

Info

Publication number
MX2021010283A
MX2021010283A MX2021010283A MX2021010283A MX2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A
Authority
MX
Mexico
Prior art keywords
methods
alcam
inhibitors
antibody compositions
present disclosure
Prior art date
Application number
MX2021010283A
Other languages
English (en)
Inventor
Stephen Connelly
Krishna Polu
Chandra Mohan
Original Assignee
Equillium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equillium Inc filed Critical Equillium Inc
Publication of MX2021010283A publication Critical patent/MX2021010283A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona métodos para tratar enfermedades inflamatorias o autoinmunes (por ejemplo, nefritis por lupus) usando inhibidores de la vía CD6-ALCAM como por ejemplo EQ001 y con métodos y pruebas de diagnóstico para identificar a sujetos quienes probablemente respondan a estos inhibidores. En particular, la presente descripción proporciona usos de diagnóstico y terapéuticos relacionados con niveles elevados de ALCAM soluble y/o proteína CD6 y fragmentos de proteína en orina y otras muestras biológicas que son indicativos de sensibilidad a inhibidores de la vía CD6-ALCAM (por ejemplo, EQ001).
MX2021010283A 2019-02-26 2020-02-26 Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus. MX2021010283A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962810628P 2019-02-26 2019-02-26
US201962933294P 2019-11-08 2019-11-08
PCT/US2020/019990 WO2020176682A1 (en) 2019-02-26 2020-02-26 Anti-cd6 antibody compositions and methods for treating lupus

Publications (1)

Publication Number Publication Date
MX2021010283A true MX2021010283A (es) 2021-09-30

Family

ID=70009403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010283A MX2021010283A (es) 2019-02-26 2020-02-26 Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.

Country Status (11)

Country Link
US (1) US20220143140A1 (es)
EP (1) EP3930751A1 (es)
JP (1) JP2022521973A (es)
CN (1) CN113490511B (es)
AU (1) AU2020229830A1 (es)
BR (1) BR112021016967A2 (es)
CA (1) CA3131299A1 (es)
MX (1) MX2021010283A (es)
SG (1) SG11202109118XA (es)
WO (1) WO2020176682A1 (es)
ZA (1) ZA202107077B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101970493A (zh) 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
US20230400466A1 (en) * 2022-05-25 2023-12-14 University Of Houston System Methods and systems for risk stratification and management of bladder cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
AU747898B2 (en) * 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
CN101970493A (zh) * 2008-03-14 2011-02-09 百康有限公司 单克隆抗体及其方法
AU2012279225A1 (en) * 2011-07-01 2014-01-16 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
MX2014010750A (es) * 2012-03-08 2015-02-05 Halozyme Inc Anticuerpos receptores del factor de crecimiento anti-epidermico condicionalmente activos y metodos de uso de los mismos.
WO2015107501A1 (en) * 2014-01-20 2015-07-23 Ghiggeri Gian Marco In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis
CN109310686B (zh) * 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
FI3468997T3 (fi) * 2016-06-08 2023-10-31 Xencor Inc Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법

Also Published As

Publication number Publication date
EP3930751A1 (en) 2022-01-05
JP2022521973A (ja) 2022-04-13
CA3131299A1 (en) 2020-09-03
US20220143140A1 (en) 2022-05-12
WO2020176682A1 (en) 2020-09-03
CN113490511B (zh) 2024-07-09
CN113490511A (zh) 2021-10-08
AU2020229830A1 (en) 2021-09-16
SG11202109118XA (en) 2021-09-29
BR112021016967A2 (pt) 2021-11-23
ZA202107077B (en) 2023-07-26

Similar Documents

Publication Publication Date Title
Gao et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Spengler et al. Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid
Salpeter et al. A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression
Harre et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
BRPI0708101B8 (pt) anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico
MX2018009738A (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
EA202090265A1 (ru) Композиции, способы и/или наборы, содержащие рекомбинантный внеклеточный домен cd38 человека
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
BR112012007365A2 (pt) proteínas de ligação à il-1
Parodi et al. Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment
BR112013009376A2 (pt) métodos para determinar isótipos de anticorpos antifármacos
MX2010006484A (es) Composiciones y metodos para detectar anticuerpos de infidelidad de transcripcion (tiab).
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
ES2657414T3 (es) Uso de la lactoferrina en el diagnóstico o el pronóstico de la enfermedad de Alzheimer
MX2021010283A (es) Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
Vora et al. Ticks elicit variable fibrinogenolytic activities upon feeding on hosts with different immune backgrounds
Nagao et al. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65–a novel Wnt/β-catenin signaling inhibitor
MX2020014095A (es) Metodos y sistemas para monitorear la salud y enfermedad de organos.
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
MX2023014389A (es) Anticuerpos anti-sirp-alfa.
AR072136A1 (es) Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
BR112023002455A2 (pt) Anticorpos fgfr3 e métodos de uso
EA201491411A1 (ru) Растворимый manf при поражениях бета-клеток поджелудочной железы